Product description: Instanyl® is a prescribed intranasal fentanyl spray for the management of breakthrough pain in adult cancer patients already receiving opioid therapy for chronic pain. Instanyl® was developed in-house by Nycomed. It was successfully launched in the EU in the second half of 2009.
Medical need: Nearly half of all early-stage cancer patients and up to 90% of those in later stages suffer the sudden onset of brief but acute ‘breakthrough’ pain. This refers to intermittent flare-ups that overcome the patient’s regular pain medication.
Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.